Compare Lam Research Corporation (LRCX) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lam Research Corporation vs Nuwellis Inc — how do they compare? Lam Research Corporation trades at $320.06 (market cap $383.63B), while Nuwellis Inc trades at $2.94 (market cap $1.09M). The key difference: Lam Research Corporation is far larger — about 351954.1× Nuwellis Inc's market cap, and Lam Research Corporation pays a 0.34% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| LRCX | NUWE | |
|---|---|---|
Market Cap | $383.63B | $1.09M |
Sector | Technology | Technology |
52-Week High | $433.33 | $527.46 |
52-Week Low | $94.84 | $2.80 |
Enterprise Value | $382.61B | -$722.58K |
Dividend Yield | 0.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lam Research (LRCX) trades at $322.00, up 2.78% today, with a bullish technical signal despite mixed moving averages. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $1.47 surpassing the $1.36 forecast. Revenue grew to $18.44B in 2025, and net income margin improved to 30.94%. Analysts maintain a strong buy consensus with a $396.06 price target, though high valuation multiples like a P/E of 57.99 and sector volatility present risks.
Outlook remains positive driven by AI-related semiconductor demand and operational efficiency, but investors face risks from elevated valuations and industry cyclicality. The stock's proximity to the $319 resistance level suggests near-term momentum could hinge on Q2 2026 earnings results against a $1.69 EPS expectation.
NUWE trades at $3.00, up 5.26% over 24 hours, following a recent 35:1 reverse stock split effective June 26, 2026. The stock shows a bearish technical signal with all moving averages indicating sell. Fundamentally, the company reported a net loss of $17.52M in 2025, with negative profit margins, though revenue grew to $8.27M. Recent news highlights expansion in pediatric care and a $6M public offering closed in June 2026.
Outlook remains challenging due to persistent losses and high cash burn, but strategic initiatives in pediatric cardiorenal care and new patents offer growth potential. Key risks include negative ROE, reliance on financing, and competitive pressures. Analyst consensus is split evenly between Buy and Hold, reflecting cautious optimism amid financial headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Lam Research Corporation
Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
